Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetylcysteine for acute uncomplicated rhinosinusitis
2019-000060-20Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine in acute rhinosinusitis (ARS) and rhinosinusitis (4 arms), sponsored by Hexal AG. Primary endpoint: Mean change from baseline in the daily MSS over the entire treatment period. Started Jun 2019; status: completed.
02
Drugs
acetylcysteine
03
Conditions
acute rhinosinusitis (ARS)rhinosinusitis
Beyond the preview
Go deeper on 2019-000060-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000060-20.